US Market News
2月前
iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping TimeApril 9, 2026 4:05 PM
NewsfileWoburn, Massachusetts--(Newsfile Corp. - April 9, 2026) - iSpecimen (NASDAQ: ISPC), an online marketplace for human biospecimens, has implemented a streamlined shipping model that enables direct shipment of biospecimens from supplier sites to customers, both domestically and internationally.By reducing reliance on centralized hub processing, the new model simplifies logistics and eliminates multi-step routing. Previously, shipments often required routing through a central hub, which could add 7-14 days to transit times. Under the updated approach, domestic shipments can now be delivered in as little as 1-2 days, reducing transit times by approximately 70-85% while also lowering overall shipping costs through fewer shipment handoffs. The updated model is supported by enhanced training and operational alignment across iSpecimen's growing global supplier network.For international shipments, iSpecimen has strengthened partnerships with key sourcing organizations across Europe and Eastern Europe, expanding access to rare and hard-to-source biospecimens. Combined with the direct-to-customer shipping model, this expanded network supports broader research requests with improved consistency and turnaround times. The company continues to maintain reliable international shipping operations, ensuring continuity of supply for time-sensitive specimens.Since its implementation earlier this year, customer feedback has been consistently positive, highlighting improvements in delivery speed, reliability, and overall experience."In addition to our AI agent, streamlining shipments is an example of the team's operational flexibility and expertise. We are pleased with improved timelines all around," commented Katie Field, CEO of iSpecimen. She continued, "Since this process improvement customers have been pleased too, for example one was 'impressed with the quality and care taken…in the careful sourcing and handling of the research materials.' We are proud that our customers use rare materials that we source to advance scientific research." About iSpecimeniSpecimen is a technology-driven marketplace that connects life science researchers with a global network of biospecimen suppliers. The Company's platform simplifies and accelerates access to human biological samples, enabling researchers to find the specimens they need to advance medical science and improve patient outcomes.Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties, including risks related to the development, performance, and adoption, and regulatory environment applicable to artificial intelligence technologies. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.For more information, visit www.ispecimen.comMedia Contactinfo@ispecimen.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/291829
Original: iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time
INV4
3月前
iSpecimen Launches AI Agent Revolutionizing Biospecimen Matching
March 12, 2026
iSpecimen Inc. (the “Company”) (NASDAQ: ISPC), a leading technology marketplace connecting researchers with biospecimen suppliers, today announced the launch of its new AI-powered Inventory Agent, a purpose-built tool designed to help accelerate the process of reviewing incoming biospecimen requests and matching them with available inventory across its global supplier network.
The internally developed AI agent analyzes incoming request criteria and is designed to identify potential biospecimen matches, enabling the iSpecimen team to respond to research inquiries with greater speed and precision. By automating the initial review and matching workflow, the technology may reduce manual workload while preserving rigorous expert oversight, ensuring quality and compliance remain paramount.
The AI-powered Inventory Agent is natively embedded within iSpecimen’s newly redesigned marketplace platform and powered by large language models (LLMs). Through an intuitive conversational interface, users can submit biospecimen requests in plain language. The system automatically extracts key criteria, including disease conditions, sample types, and diagnostic test requirements, and dynamically searches across configured inventory sources to surface potential matches. Results are ranked by relevance and presented with comprehensive supporting details, empowering the iSpecimen team to evaluate candidate biospecimens quickly and confidently.
“Optimizing the marketplace for human biospecimens has been the founding mission of iSpecimen since day one. The launch of our AI agent marks a significant milestone in that journey, one that we believe will meaningfully enhance outcomes for our suppliers, our customers, and ultimately the researchers advancing scientific discovery around the world,” commented Katie Field, Chief Executive Officer.
This launch represents the first in a series of planned AI-driven capabilities designed to modernize the end-to-end biospecimen sourcing experience. Building on this foundation, iSpecimen expects to introduce features including automated monitoring and validation of regulatory submissions, further automation of high-compliance and data-intensive workflows, and intelligent lead qualification and outreach management, all aimed at reducing friction and accelerating access to critical research samples.
Together, these advancements underscore iSpecimen’s commitment to harnessing cutting-edge technology to serve the evolving needs of the global research community.
About iSpecimen
iSpecimen is a technology-driven marketplace that connects life science researchers with a global network of biospecimen suppliers. The Company’s platform simplifies and accelerates access to human biological samples, enabling researchers to find the specimens they need to advance medical science and improve patient outcomes.
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties, including risks related to the development, performance, and adoption, and regulatory environment applicable to artificial intelligence technologies. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.
Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, visit www.ispecimen.com
Media Contact
info@ispecimen.com
Link article
🗞️ 🤓
US Market News
3月前
iSpecimen Launches AI Agent Revolutionizing Biospecimen MatchingMarch 12, 2026 4:05 PM
NewsfileStrengthens iSpecimen's next-generation marketplace platformWoburn, Massachusetts--(Newsfile Corp. - March 12, 2026) - iSpecimen Inc. (NASDAQ: ISPC) (the "Company"), a leading technology marketplace connecting researchers with biospecimen suppliers, today announced the launch of its new AI-powered Inventory Agent, a purpose-built tool designed to help accelerate the process of reviewing incoming biospecimen requests and matching them with available inventory across its global supplier network.The internally developed AI agent analyzes incoming request criteria and is designed to identify potential biospecimen matches, enabling the iSpecimen team to respond to research inquiries with greater speed and precision. By automating the initial review and matching workflow, the technology may reduce manual workload while preserving rigorous expert oversight, ensuring quality and compliance remain paramount.The AI-powered Inventory Agent is natively embedded within iSpecimen's newly redesigned marketplace platform and powered by large language models (LLMs). Through an intuitive conversational interface, users can submit biospecimen requests in plain language. The system automatically extracts key criteria, including disease conditions, sample types, and diagnostic test requirements, and dynamically searches across configured inventory sources to surface potential matches. Results are ranked by relevance and presented with comprehensive supporting details, empowering the iSpecimen team to evaluate candidate biospecimens quickly and confidently."Optimizing the marketplace for human biospecimens has been the founding mission of iSpecimen since day one. The launch of our AI agent marks a significant milestone in that journey, one that we believe will meaningfully enhance outcomes for our suppliers, our customers, and ultimately the researchers advancing scientific discovery around the world," commented Katie Field, Chief Executive Officer.This launch represents the first in a series of planned AI-driven capabilities designed to modernize the end-to-end biospecimen sourcing experience. Building on this foundation, iSpecimen expects to introduce features including automated monitoring and validation of regulatory submissions, further automation of high-compliance and data-intensive workflows, and intelligent lead qualification and outreach management, all aimed at reducing friction and accelerating access to critical research samples.Together, these advancements underscore iSpecimen's commitment to harnessing cutting-edge technology to serve the evolving needs of the global research community.About iSpecimeniSpecimen is a technology-driven marketplace that connects life science researchers with a global network of biospecimen suppliers. The Company's platform simplifies and accelerates access to human biological samples, enabling researchers to find the specimens they need to advance medical science and improve patient outcomes. Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties, including risks related to the development, performance, and adoption, and regulatory environment applicable to artificial intelligence technologies. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.For more information, visit www.ispecimen.com.Media Contact
info@ispecimen.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/288192
Original: iSpecimen Launches AI Agent Revolutionizing Biospecimen Matching
US Market News
4月前
iSpecimen Announces Milestone 2: System Integration and Marketplace Activation CompleteFebruary 6, 2026 9:30 AM
NewsfileLive Production Marketplace Now AvailableWoburn, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone delivers a fully integrated, live marketplace that connects customer requests with supplier inventories, enabling streamlined operations, reduced costs, and a foundation for future growth.Chief Executive Officer Ms. Katie Field commented, "This Milestone 2 achievement demonstrates end-to-end system integration, legacy data migration, and activation of a production-ready SalesStack marketplace. We are pleased this will deliver operational continuity and scalable growth for our customers and vendors alike." Key achievements of the Milestone 2 phase include: End-to-End System Integration Connected the new SalesStack marketplace to core internal systems, enabling seamless data flow across customer, supplier, and transaction services.Legacy Data Migration Successfully migrated all historical user, order, and supplier data from the legacy marketplace into the new SalesStack platform.Production Marketplace Launch Activated the new platform for live use, now available at: Production: https://mp.ispecimen.comCore Feature Enablement Delivered essential marketplace functionality required for full operational workflows, including order processing, user management, and supplier connectivity.Enhanced AI-Driven Matching (customer requests and supplier inventories) In line with industry efforts to leverage AI for demand-supply matching, the marketplace now supports AI-assisted matching to more efficiently connect customer requests with available supplier inventories.Ms. Field continued, "Milestone 2 validates our approach to a connected, AI-informed marketplace. By unifying data and automating core workflows, we're delivering tangible value to customers and suppliers while laying the groundwork for rapid growth."The Company noted business benefits of this second stage:Operational Continuity & Stability: The new platform is fully connected to internal systems, enabling live, end-to-end marketplace operations and reducing manual handoffs.Cost Optimization: As part of the legacy system sunset process, the company will begin downsizing infrastructure supporting the old marketplace, significantly reducing AWS operating expenses.Improved Scalability & Performance: The new architecture enables faster feature delivery, improved system reliability, and the ability to scale with customer demand.Foundation for Revenue Growth: With system integration and live marketplace activation complete, iSpecimen is positioned to accelerate supplier onboarding, pricing automation, and new customer acquisition in subsequent phases.Next steps of the Salestack roll out include expanding supplier onboarding and pricing automation to shorten time-to-market for new suppliers and to enable dynamic, price-competitive listings. We will roll out AI-driven match capabilities at scale to improve precision in connecting customer requests with supplier inventories, reducing manual intervention and accelerating order fulfillment. We will continue the sunset of legacy infrastructure, migrating workloads and data to the SalesStack platform while ensuring uninterrupted service, security, and compliance throughout the transition. Finally, the Company intends to prepare for Milestone 3 by planning additional marketplace features, broader geographic rollout, and deeper integrations with partner ecosystems to drive growth, resilience, and a more seamless buyer-supplier experience.About iSpecimen Inc.iSpecimen Inc. (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.For further information, please contact:info@ispecimen.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/282776
Original: iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete
US Market News
4月前
iSpecimen Achieves Rapid Procurement Milestone for Influenza ResearchFebruary 6, 2026 8:20 AM
NewsfileLexington, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ: ISPC), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the strength, responsiveness, and reliability of its site network.Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected 500 influenza swab samples in just a few weeks to support a customer research project—demonstrating its ability to respond quickly to time-sensitive research needs. The rapid turnaround and quality of the specimens have led to continued engagement with the customer in future respiratory sampling needs.In addition to respiratory specimens, iSpecimen continues to consistently maintain supply of cerebrospinal fluid (CSF) to support ongoing customer studies. The company is also experiencing increased interest from clients seeking support across a broader range of specimen types, including FFPE and fresh frozen (FF) tissue, reflecting growing demand for reliable and diverse biospecimen sourcing.Customer feedback continues to reinforce iSpecimen's commitment to quality and transparency. One recent customer shared:"We were very excited upon receiving the urine specimens from iSpecimen and have begun to review all the information we received about the 20 samples. I must say that we are very impressed with their quality, and their extensive documentation."The customer also indicated their intent to mention iSpecimen as the sample source in public discussions and publications, underscoring confidence in both specimen quality and accompanying documentation.These accomplishments highlight iSpecimen's ongoing commitment to providing timely access to well-documented biospecimens that support critical research and scientific advancement.About iSpecimen Inc.iSpecimen Inc. (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.For further information, please contact:info@ispecimen.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/282770
Original: iSpecimen Achieves Rapid Procurement Milestone for Influenza Research
subslover
9月前
iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions
Newsfile Corp.
Newsfile Corp
Woburn, Massachusetts--(Newsfile Corp. - September 4, 2025) - iSpecimen Inc. (NASDAQ: ISPC), (the "Company"), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced an update on its major strategic initiative aimed at integrating digital assets into its business model. The Company had previously announced that it is pursuing a strategic initiative aimed at integrating digital assets into its business model, by seeking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.
Since announcing its intentions in August, iSpecimen has been approached by several Crypto currency-related companies that have presented opportunities in tokenized real-world assets as well as among highly ranked cryptocurrencies. In a parallel path, the Company has continued meetings to build a Solana-based treasury program.
"We are refining our approach to build a digital asset treasury. While the acquisition of Locked Solana appeals, we recognize there are many opportunities that we continue to explore," commented Mr. Robert Lim CEO of iSpecimen.
As for Solana, iSpecimen plans to establish a SOL-based treasury program to diversify the Company's balance sheet and to support long-term growth initiatives. ISPC intends to source treasury management expertise to assist with policy design, counterparty diligence, execution, custody coordination, risk management, and reporting. The Company expects to fund the treasury program primarily from capital that may be raised from time to time.
To dive deeper, the Company's planned treasury program contemplates purchasing SOL (the native token of the Solana network) including, where appropriate, Locked SOL, through over-the-counter transactions with reputable cryptocurrency institutions. Any such purchases will be made only where legally transferable and following legal, regulatory, and counterparty due diligence. "Locked SOL" refers to SOL subject to contractual transfer or vesting restrictions; pricing may reflect a discount to prevailing spot prices to compensate for illiquidity and lock-up risk. The Company may also purchase unlocked SOL on regulated or reputable venues for liquidity management.
Mr. Lim continued, "We plan to deliver shareholder value primarily through a buy and HODL strategy as well as by purchasing locked SOL at a discount. We plan for the Solana to be staked including liquid staking tokenization to increase yields for shareholders in the long-term. Nevertheless, we also plan to partially diversify our Solana holding and allow a small percentage for spot trading." A HODL strategy is a long-term investment approach in Cryptocurrency to hold assets even in times of market volatility, rather than trying to time the market by frequently buying and selling.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About iSpecimen
iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.
Safe Harbor Statement
subslover
1年前
8k out. On February 19, 2025, the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) appointed Ms. Katharyn Field as President of the Company, effective immediately. In connection with her appointment, Ms. Field resigned as a member of the Board, and Ms. Siyun Yang was appointed as an independent director to fill the resulting vacancy, effective immediately.
Ms. Yang has also been appointed to serve on the Audit Committee and Nominating and Corporate Governance Committee of the Board, replacing Ms. Field. Additionally, the Board appointed Mr. Richard Paolone as Chair of the Board, replacing Ms. Field in this role. Mr. Robert Bradley Lim remains the Company’s Chief Executive Officer and a member of the Board.
The compensation arrangements for Ms. Field in connection with her appointment as President have not yet been determined. The Company will disclose the material terms of any such arrangements in an amendment to this Current Report on Form 8-K or in another applicable filing once finalized.
Ms. Yang is an Associate Attorney at Quill & Arrow LLP based in Los Angeles, California, where she specializes in consumer protection and product liability litigation. Previously, she served as In-House Counsel at Halo Collective Inc., overseeing regulatory compliance, corporate transactions, and litigation matters related to cannabis operations and intellectual property. Prior to that, Ms. Yang was a Provisional Licensed Lawyer at Di Li Law, PC, where she focused on trademark filings, oppositions, and intellectual property matters. Ms. Yang holds an LL.M. in International Comparative Law from UCLA School of Law and an LL.B. in International Economic Law from East China University of Political Science and Law. Her expertise in litigation, corporate governance, and data analytics further strengthens the Board’s oversight capabilities. There are no arrangements or understandings between Ms. Yang and any other person pursuant to which she was selected as a director, nor are there any related party transactions between the Company and Ms. Yang that would require disclosure under Item 404(a) of Regulation S-K.
The Board and management team remain focused on executing the Company’s objectives and do not anticipate any disruption to the Company’s operations as a result of these leadership changes.
subslover
1年前
Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus (hMPV). The virus has been causing hospitals in China to become overrun, raising the potential for another COVID-style pandemic. iSpecimen is a market leader in the biospecimen space and leverages its vast network of suppliers to procure specimens for the anticipated potential demand that may come with the need to study this disease and develop a vaccine to address it.
Human metapneumovirus (hMPV) is a virus which causes upper respiratory infections. While those infected with hMPV typically present with only mild symptoms, it can make some people very sick and cause death in the elderly, immunocompromised, and those with chronic conditions. There is currently no vaccine for hMPV, hence the potential need for samples if a company were looking to make this type of breakthrough drug or study the virus.
With the devastation of COVID 5 years ago, there is concern in some areas that the virus could cause similar problems as it spreads in a very similar fashion through respiratory droplets from coughing or sneezing, close personal contact and touching contaminated surfaces before contacting the mouth, nose, or eyes. hMPV is very difficult to differentiate from COVID-19, flu, and respiratory syncytial virus (RSV), and unlike these viruses there is no vaccine for hMPV.
The potential demand for hMPV specimens continues to grow as hMPV remains a significant area of attention in the news and concern among the general population. The potential demand for a vaccine for this fast spreading disease highlights the critical need for reliable access to high-quality specimens. iSpecimen is poised to address this need through its strategic global partnerships with high value suppliers and streamlining of specimen procurement.
About iSpecimen
subslover
2年前
iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
Newsfile Corp.
Newsfile Corp
Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its Next Day Quote Program ("NDQ"). This next-day quote service for researchers and providers is tailored to accelerate the biospecimen transaction process and delivers accurate biospecimen sample pricing within 24 hours of receiving the customer request. Next Day Quotes are possible to implement only when the Company knows the supplier's data on their specific capabilities and pricing, as well as understands the customer's requirements.
Recognizing the need for timely access to high-quality biospecimens to advance life science research, iSpecimen had introduced NDQ to offer researchers and providers with swift and accurate sample pricing. From fresh whole blood and prescreened mutation-characterized blocks to an array of clinically collected remnant, banked and prospective biospecimens, most quotes are provided within a day of receiving the inquiry.
Since introducing the program in 2023 and the recently completed build of a search tool, quotes can be created within minutes. With this capability, the Company's sales mix has increasingly shifted towards NDQ. In November 2024, 30% of all sales opportunities were Next Day Quotes. Of all quotes that were generated in November 2024, 48% were Next Day Quotes. Meanwhile, the conversion rate was high for Next Day Quotes. 60% of all purchase orders were Next Day Quotes1.
Leslie Hoyt, Senior Vice President of Operations commented, "Our customers have responded enthusiastically to iSpecimen's Next Day Quote Program. For the first six months of the program, NDQ has consistently yielded strong results, driving an estimated 60% of sales. The data continue to show that if we quote within the next business day, we greatly increase the likelihood of receiving a signed purchase order. Current and future customers respond positively because time matters."
Ms. Hoyt further commented, "We continue to enhance our internal databases and search tools to proactively harvest data, ensuring the viability of Next day Quote program while increasing the frequency with which Next Day Quotes are possible. This offering accelerates our operational timeline and the customer decision journey. Ultimately next day quotes allow researchers and providers to focus on what matters most, and iSpecimen to be a valuable service provider for all customers."
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
81vette
2月前
Zardiw
2月前
glenn1919
2月前
MomsSpaghetti
3月前
tw0122
7月前
billionareboysclub
9月前
oldstocks
9月前
Monksdream
1年前
peterus
1年前
TrendTrade2016
2年前
メールアドレスで登録
